We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study
Read MoreHide Full Article
Shares of Sigilon Therapeutics, Inc. plunged 25.3% after the company announced that the FDA placed a clinical hold on its phase I/II study evaluating its pipeline candidate SIG-001 in patients with severe or moderately severe hemophilia A.
The clinical hold came in place following the clinical stage biotechnology company’s announcement of a serious adverse event (SAE) and a temporary enrollment halt.
We note that SIG-001 is the company’s most advanced and investigational therapy in development to prevent bleeding episodes in patients with moderate-severe to severe hemophilia A.
Three patients have been dosed with SIG-001 to date. The third patient who received the highest dose of the study drug developed inhibitors to Factor VIII (FVIII), a well-known complication of FVIII therapy.
Consequently, the FDA requested additional information or data on factors potentially contributing to the development of inhibitors in this patient, such as family history and immune stimulation from a recent vaccination. The three patients enrolled in this study will continue to be under observation per study protocol.
The setback will delay the development of the candidate, which was granted an Orphan Drug designation to treat hemophilia A by the FDA in August 2019 and EMA in November 2020.
This apart, the company is developing SIG-009 for patients with Factor VII deficiency and SIG-003 for patients with Hemophilia B.
The stock has slumped 86.9% so far this year compared with the industry’s decrease of 8.3%.
Image Source: Zacks Investment Research
Other candidates in the company’s pipeline include SIG-007 (developed for patients with a confirmed diagnosis of Fabry disease), SIG-018 for patients with mucopolysaccharidosis type 2 or MPS-2 and SIG-020 for patients with mucopolysaccharidosis type 6 or MPS-6. The company is also developing SIG-002 for the treatment of type 1 Diabetes in collaboration with Eli Lilly.
Treatments approved for hemophilia A include Roche’s (RHHBY - Free Report) hemophilia A and Novo Nordisk’s (NVO - Free Report) NovoSeven among others.
Zoetis’ earnings estimates have been revised 7 cents upward for 2021 and 9 cents for 2022 over the past 90 days. The stock has rallied 16.5% year to date.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study
Shares of Sigilon Therapeutics, Inc. plunged 25.3% after the company announced that the FDA placed a clinical hold on its phase I/II study evaluating its pipeline candidate SIG-001 in patients with severe or moderately severe hemophilia A.
The clinical hold came in place following the clinical stage biotechnology company’s announcement of a serious adverse event (SAE) and a temporary enrollment halt.
We note that SIG-001 is the company’s most advanced and investigational therapy in development to prevent bleeding episodes in patients with moderate-severe to severe hemophilia A.
Three patients have been dosed with SIG-001 to date. The third patient who received the highest dose of the study drug developed inhibitors to Factor VIII (FVIII), a well-known complication of FVIII therapy.
Consequently, the FDA requested additional information or data on factors potentially contributing to the development of inhibitors in this patient, such as family history and immune stimulation from a recent vaccination. The three patients enrolled in this study will continue to be under observation per study protocol.
The setback will delay the development of the candidate, which was granted an Orphan Drug designation to treat hemophilia A by the FDA in August 2019 and EMA in November 2020.
This apart, the company is developing SIG-009 for patients with Factor VII deficiency and SIG-003 for patients with Hemophilia B.
The stock has slumped 86.9% so far this year compared with the industry’s decrease of 8.3%.
Image Source: Zacks Investment Research
Other candidates in the company’s pipeline include SIG-007 (developed for patients with a confirmed diagnosis of Fabry disease), SIG-018 for patients with mucopolysaccharidosis type 2 or MPS-2 and SIG-020 for patients with mucopolysaccharidosis type 6 or MPS-6. The company is also developing SIG-002 for the treatment of type 1 Diabetes in collaboration with Eli Lilly.
Treatments approved for hemophilia A include Roche’s (RHHBY - Free Report) hemophilia A and Novo Nordisk’s (NVO - Free Report) NovoSeven among others.
Zacks Rank & Stock to Consider
Sigilon currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Zoetis, Inc. (ZTS - Free Report) , which carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zoetis’ earnings estimates have been revised 7 cents upward for 2021 and 9 cents for 2022 over the past 90 days. The stock has rallied 16.5% year to date.